Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$7.79 USD

7.79
1,013,423

+0.04 (0.52%)

Updated May 10, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Technology Services

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Allscripts (MDRX) Stock Now

Strong prospects in Sunrise EHR platform to aid Allscripts (MDRX). However, intense competition in the MedTech space is a headwind.

    Implied Volatility Surging for Allscripts (MDRX) Stock Options

    Investors need to pay close attention to Allscripts (MDRX) stock based on the movements in the options market lately.

      Nabaparna Bhattacharya headshot

      Allscripts' Sunrise Abstracting Selected by Wyckoff Heights

      Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.

        Cerner (CERN) Strong on EHR Prospects, Competition Intense

        Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.

          Allscripts' Payerpath & ePrescribe Receive EHNAC Accreditation

          Accreditation by EHNAC indicates Allscripts' (MDRX) sustainability in health data processing and transactions in terms of industry-established standards and HIPAA regulations.

            Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells

            Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.

              Allscripts Gains From Strong Results in Q2, Competition Rife

              Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.

                Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates

                Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.

                  AllScripts Healthcare (MDRX) Matches Q2 Earnings Estimates

                  AllScripts (MDRX) delivered earnings and revenue surprises of 0.00% and 0.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                    Why Is Allscripts Healthcare (MDRX) Up 9.8% Since Its Last Earnings Report?

                    Allscripts Healthcare (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Allscripts' iPro Anesthesia to be Administered by SingHealth

                      Allscripts (MDRX) goes global, joining hands with Singapore-based hospital to implement iPro Anesthesia.

                        Allscripts Acquires HealthGrid to Improve Patient Outcome

                        Allscripts' (MDRX) HealthGrid buyout to drive FollowMyHealth platform.

                          Allscripts (MDRX) Q1 Earnings & Revenues Lag, Bookings Rise

                          Allscripts (MDRX) witnesses strong segmental performances; a solid guidance encourages.

                            Nabaparna Bhattacharya headshot

                            MedTech Takes to Big Data Analytics: 3 Stocks Catch Eye

                            Here we take a look at the major factors that are driving the importance of big data in the MedTech space.

                              Why Is Allscripts (MDRX) Down 11.3% Since its Last Earnings Report?

                              Allscripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Nabaparna Bhattacharya headshot

                                Is the Tax Repeal Only Glitter and No Gold for MedTech?

                                While the MedTech fraternity is hopeful about the latest MedTech tax repeal, we would like to draw your attention to the slump in share price and net margin figures following the tax's abolition in 2015.

                                  Allscripts (MDRX) Launches Avenel to Revamp EHR Platform

                                  Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.

                                    Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition

                                    Allscripts' (MDRX) promising fourth-quarter results and international hold are encouraging. Integration risks and cutthroat competition are likely to mar prospects.

                                      Allscripts (MDRX) Q4 Earnings Meet, Revenues Beat Estimates

                                      Solid year-over-year growth in Client Services revenues drove Allscripts in Q4.

                                        Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates

                                        Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.

                                          Allscripts Rides High on Product Launches Amid Rising Costs

                                          Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.

                                            Allscripts' Latest Initiative Eradicates Price Ambiguity

                                            Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.

                                              Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN

                                              The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.

                                                Allscripts (MDRX) Up 13.3% Since Earnings Report: Can It Continue?

                                                Allscripts (MDRX) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Allscripts, Elligo Health Enter in Strategic Partnership

                                                  Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.